Every so often I type
“Primary Central Nervous System Lymphoma” into a search on Google. This week I
came up with some very promising information. Two abstracts from the same group
based at University of California San Francisco are shown here. While the
second is rather vague, the first looks most encouraging. The regimen is a
slight variant on the one I received, and although our decision to forego
radiation therapy was based on concerns about potential complications given my
pulmonary issues, this would seem to suggest that my prognosis may be about the
same even if I had decided to move forward with it.
Intensive chemotherapy and immunotherapy
in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance
50202).
Source
Helen
Diller Comprehensive Cancer Center, University of California, San Francisco, CA
94143, USA.
Abstract
PURPOSE:
Concerns regarding neurocognitive toxicity of whole-brain
radiotherapy (WBRT) have motivated development of alternative, dose-intensive
chemotherapeutic strategies as consolidation in primary CNS lymphoma (PCNSL).
We performed a multicenter study of high-dose consolidation, without WBRT, in
PCNSL. Objectives were to determine: one, rate of complete response (CR) after
remission induction therapy with methotrexate, temozolomide, and rituximab
(MT-R); two, feasibility of a two-step approach using high-dose consolidation
with etoposide plus cytarabine (EA); three, progression-free survival (PFS);
and four, correlation between clinical and molecular prognostic factors and
outcome.
PATIENTS
AND METHODS:
Forty-four patients with newly diagnosed PCNSL were treated with
induction MT-R, and patients who achieved CR received EA consolidation. We
performed a prospective analysis of molecular prognostic biomarkers in PCNSL in
the setting of a clinical trial.
RESULTS:
The rate of CR to MT-R was 66%. The overall 2-year PFS was 0.57,
with median follow-up of 4.9 years. The 2-year time to progression was 0.59,
and for patients who completed consolidation, it was 0.77. Patients age > 60
years did as well as younger patients, and the most significant clinical
prognostic variable was treatment delay. High BCL6 expression correlated with
shorter survival.
CONCLUSION:
CALGB 50202 demonstrates for the first time to our knowledge that
dose-intensive consolidation for PCNSL is feasible in the multicenter setting
and yields rates of PFS and OS at least comparable to those of regimens
involving WBRT. On the basis of these encouraging results, an intergroup study
has been activated comparing EA consolidation with myeloablative chemotherapy
in this randomized trial in PCNSL, in which neither arm involves WBRT.
J Clin Oncol. 2013 Sep 1;31(25):3061-8. Doi:
10.1200/JCO.2012.46.9957. Epub 2013 Apr 8.
How I treat CNS lymphomas
Abstract
The pathogenesis of primary and secondary CNS lymphoma poses a
unique set of diagnostic, prognostic and therapeutic challenges. During the
past ten years there has been significant progress in the elucidation of the
molecular properties of CNS lymphomas and their microenvironment as well as
evolution in the development of novel treatment strategies. Once assumed to be
uniformly associated with a dismal prognosis, it is now reasonable to
anticipate long-term survival and possibly cure for a significant fraction of
CNS lymphoma patients. The pathogenesis of CNS lymphomas impacts multiple
compartments within the neuroaxis and proper management of the CNS lymphoma
patient requires a multidisciplinary team with expertise not only in
Hematology/Oncology but also in Neurology, Neuroradiology, Neurosurgery,
Clinical Neuropsychology, Ophthalmology, Pathology and Radiation Oncology.
Given the evolving principles of management and the evidence for improvements
in survival, our goal is to provide an overview of current knowledge regarding
the pathogenesis of CNS lymphomas, and to highlight promising strategies that
we believe to be most effective in establishing diagnosis, staging, as well as
therapeutic management.
Blood August 20, 2013 blood-2013-06-453084
When Barry was
completing his Ph.D. at the University of Rochester back in 1978, he had two
opportunities for postdoctoral fellowships: one at Brookhaven National
Laboratory on Long Island, and the other at University of California San
Francisco. Simmie was less than a year old at the time, and the idea of moving
so far away seemed rather overwhelming. It was difficult enough just leaving
the wonderful medical team at Strong Memorial Hospital who had cared for Simmie
(born 12 weeks premature) and me (severe preeclampsia). Yet I have sometimes
wondered how different our lives would have been had we jumped at the chance to
spend time in that beautiful city. Of course now it turns out that the crime
rate in San Francisco has increased while New York has become the much kinder
and gentler of the two cities.
The weather reports
predict a beautiful weekend here in the Northeast. Barry will not be returning from the UK until
Sunday evening, but our daughters and their families are taking good care of
me.
Have a wonderful
weekend!
Love,
Rebecca